Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Hiroaki Araie"'
Publikováno v:
HemaSphere, Vol 7, p e6714808 (2023)
Externí odkaz:
https://doaj.org/article/6e4c0ac7d0824c16a2c8ab3473fec9e6
Autor:
Hiroaki Araie, Toshiki Tasaki, Naoko Hosono, Tetsuya Tsujikawa, Hidehiko Okazawa, Takahiro Yamauchi
Publikováno v:
Annals of Hematology.
Autor:
Miyuki Ookura, Yasufumi Matsuda, Mihoko Morita, Kazuhiro Itoh, Takahiro Yamauchi, Naoko Hosono, Hiroaki Araie
Publikováno v:
International Journal of Hematology. 113:362-369
We retrospectively evaluated the clinical efficacy and toxicity of gemtuzumab ozogamicin (GO) in patients with relapsed acute myeloid leukemia (AML). Nineteen patients (median 70 years) received GO (9 mg/m2, days 1 and 15) as salvage therapy in our i
Autor:
Masahide Osaki, Takanobu Morishita, Motohito Okabe, Marie Ohbiki, Takahiko Sato, Yoon-ha Lee, Yukiyasu Ozawa, Tatsunori Goto, Koichi Miyamura, Yuuka Kawaguchi, Miyo Goto, Hiroaki Araie
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:2509-2516
Noninfectious transplantation-related complications (TRCs) such as graft-versus-host disease (GVHD) and endothelial cell damage (TRC-EC) are critical after allogeneic hematopoietic stem cell transplantation. Tacrolimus (TAC) is used to control GVHD.
Autor:
Yuka Kawaguchi, Koichi Miyamura, Takanobu Morishita, Miyo Goto, Tatsunori Goto, Yukiyasu Ozawa, Yoon-ha Lee, Tomoe Ichiki, Marie Ohbiki, Masahide Osaki, Motohito Okabe, Hiroaki Araie
Publikováno v:
Clinical transplantationREFERENCES. 34(10)
BACKGROUND Early tacrolimus (TAC) concentrations correlate with the risk of acute graft-versus-host disease (aGVHD); however, whether the variability of early TAC concentrations after allo-HSCT governs the occurrence of aGVHD remains unknown. Here, w
Autor:
Kazuhiro Itoh, Hiroko Shigemi, Hiromichi Iwasaki, Yuki Shimamoto, Hiroaki Araie, Takahiro Yamauchi
Publikováno v:
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 27(2)
Enterococci is one of a major cause of bloodstream infection (BSI). Because of its intrinsic drug-resistant nature, empiric antibiotic treatment tends to be inappropriate. We conducted a single-center retrospective cohort study to evaluate the impact
Autor:
Masahide, Osaki, Yoonha, Lee, Yoko, Osamura, Tomoe, Ichiki, Motohito, Okabe, Yuka, Kawaguchi, Marie, Obiki, Ai, Ito, Miyo, Goto, Hiroaki, Araie, Tatsunori, Goto, Takanobu, Morishita, Yukiyasu, Ozawa, Masafumi, Ito, Koichi, Miyamura
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 61(3)
A 54-year-old man with acute myeloid leukemia (AML) underwent allogeneic bone marrow transplantation from a human leukocyte antigen-matched unrelated donor in nonremission status. Bone marrow aspiration performed on day 14 showed that the patient had
Autor:
Marie Ohbiki, Hiroaki Araie, Yuka Kawaguchi, Yoon-ha Lee, Yukiyasu Ozawa, Miyo Goto, Tatsunori Goto, Koichi Miyamura, Takanobu Morishita, Masahide Osaki, Motohito Okabe
Publikováno v:
International journal of hematology. 110(5)
Malnutrition before allogeneic hematopoietic cell transplantation (allo-HCT) is associated with poor clinical outcomes. Herein, we evaluated the predictive value of controlling nutritional status (CONUT) in patients undergoing allo-HCT for myeloid ma
Autor:
Kana Oiwa, Naoko Hosono, Takanori Ueda, Shinji Kishi, Kazuhiro Itoh, Toshiki Tasaki, Katsunori Tai, Satoshi Ikegaya, Yasufumi Matsuda, Takahiro Yamauchi, Miyuki Okura, Hiroaki Araie, Ippei Sakamaki
Publikováno v:
Internal Medicine
Objective We retrospectively compared the clinical efficacy and toxicity of rituximab (R)-THP-COP (pirarubicin, cyclophosphamide, vincristine, and prednisolone) with that of R-CHOP (rituximab, adriamicin, cyclophosphamide, vincristine, and prednisolo
Autor:
Tomoe Ichiki, Yoon-ha Lee, Masahide Osaki, Miyo Goto, Tatsunori Goto, Koichi Miyamura, Takahiko Sato, Motohito Okabe, Marie Ohbiki, Hiroaki Araie, Yuka Kawaguchi, Yukiyasu Ozawa, Takanobu Morishita
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S117
Introduction and Objectives Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is briefly defined as an AML which have multilineage dysplasia (MLD), a history of myelodysplastic syndrome (MDS) and/or an MDS-related cytogenetic abnor